Premium
Outcome of sirolimus‐based immunosuppression, fifteen years post–live‐donor kidney transplantation: Single‐center experience
Author(s) -
Hamdy Ahmed F,
Elhadedy Muhammed A,
Donia Ahmed F,
Taha Noheir M,
Bakr Mohamed A
Publication year - 2019
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/ctr.13463
Subject(s) - medicine , immunosuppression , sirolimus , tacrolimus , transplantation , single center , kidney transplantation , surgery , urology , randomized controlled trial , creatinine , renal function
In a prospective randomized controlled trial, between May 2001 and January 2003, 132 live‐donor kidney transplant recipients were randomized to receive sirolimus primary immunosuppression, either in combination with low dose tacrolimus (Tac group) or in combination with mycophenolate mofetil ( MMF group). We have previously reported on 2‐ and 5‐year follow‐up results, with favorable patient and graft outcomes obtained in both groups. In view of recent published reports of increased risk of inferior outcomes among sirolimus‐treated patients, we herein present results of an observational extension of the previously randomized patients 15 years post‐transplantation. Mortality rates were 10.8% and 3% in Tac and MMF groups respectively after mean follow‐up period of 11.2‐11.8 years. Comparable graft survival rates were obtained in both groups ranging from 60% to 62.7%. The ( MMF ) group continued to have the advantage of remaining on primary plan of immunosuppression (56.7% of patients) as well as to maintain better graft function in terms of serum creatinine level. Herein, we presented longest term published data for sirolimus‐based immunosuppression among live‐donor kidney transplants with favorable outcome in terms of survival and graft function.